Table 1 Characteristics of the patients whose tissue was assessed on TMAs in this study (as at baseline in the AZURE study).
Characteristic | CD73 dataset | Full AZURE Trial population | ||
|---|---|---|---|---|
Control (n = 204) | Zoledronate (n = 218) | Control (n = 1678) | Zoledronate (n = 1681) | |
Age (years) Median (Range) | 53 (30–79) | 52 (26–77) | 51 (20–87) | 51 (21–89) |
Tumour stage | ||||
T1 | 66 (32.35) | 77 (34.84) | 523 (31.2) | 542 (32.2) |
T2 | 104 (50.98) | 117 (52.94) | 867 (51.7) | 851 (50.6) |
T3 | 32 (15.69) | 22 (9.95) | 228 (13.6) | 227 (13.5) |
T4 | 2 (0.98) | 5 (2.26) | 59 (3.5) | 58 (3.5) |
Neo-adjuvant therapy | ||||
Yes | 2 (0.98) | 7 (3.17) | 1564 (97.60) | 1598 (93 − 50) |
No | 202 (99.02) | 214 (96.83) | 38 (2.40) | 104 (6.50) |
Systemic therapy plan | ||||
Endocrine Therapy Alone | 13 (6.37) | 18 (8.14) | 74 (4.5) | 76 (4.5) |
Chemotherapy Alone | 50 (24.51) | 41 (18.55) | 360 (21.5) | 362 (21.5) |
Endocrine and Chemotherapy | 141 (69.12) | 162 (73.30) | 1243 (74.1) | 1243 (73.9) |
Anthracyclines | ||||
Yes | 186 (91.18) | 207 (90) | 1564 (97.6) | 1564 (97.6) |
No | 18 (8.82) | 23 (11.11) | 38 (2.4) | 38 (2.4) |
Taxanes | ||||
Yes | 31 (15.20) | 30 (13.57) | 385 (24.0) | 390 (24.3) |
No | 173 (84.80) | 191 (86.43) | 1219 (76.0) | 1215 (75.7) |
Use of statins | ||||
Yes | 12 (5.88) | 12 (5.43) | 101 (60) | 97 (5.8) |
No | 192 (94.12) | 209 (94.57) | 67 (40) | 1575 (94.2) |
Menopausal status | ||||
Pre-menopausal | 92 (45.10) | 94 (43.53) | 752 (44.8) | 751 (44.7) |
≤ 5 years since menopause | 38 (18.63) | 35 (15.84) | 244 (14.5) | 247 (14.7) |
> 5 years since menopause | 58 (28.43) | 69 (31.22) | 522 (30.9) | 519 (30.9) |
Menstrual status unknown | 16 (7.84) | 23 (10.40) | 160 (9.5) | 164 (9.8) |
ER status | ||||
ER Positive | 155 (76.35) | 177 (80.09) | 1316 (78.4) | 1319 (78.5) |
ER Negative | 48 (23.65) | 44 (19.90) | 355 (21.2) | 349 (20.8) |
Status Unknown | 0 | 0 | 7 (0.4) | 13 (0.8) |
PR status | ||||
PR Positive | 70 (34.31) | 76 (34.90) | 698 (41.6) | 725 (43.1) |
PR Negative | 44 (21.57) | 40 (18.10) | 424 (25.3) | 382 (22.7) |
Status Unknown | 88 (43.14) | 104 (47.06) | 548 (32.7) | 571 (34.0) |
Missing | 2 (0.98) | 0 | 1 (0.45) | 0 |
Lymph node involvement | ||||
1–3 Nodes involved | 132 (65.02) | 144 (65.45) | 1032 (61.5) | 1041 (61.9) |
≥ 4 Nodes involved | 70 (34.48) | 76 (34.55) | 608 (36.2) | 604 (35.9) |
Unknown Involvement | 1 (0.49) | 0 | ||
Missing Data | 0 | 0 | ||
HER2 status | ||||
HER2 Positive | 29 (14.29) | 21 (9.50) | 223 (13.3) | 192 (11.4) |
HER2 Negative | 52 (25.62) | 66 (29.86) | 603 (35.9) | 648 (38.5) |
Unknown/ Not Measured | 121 (59.61) | 132 (59.73) | 843 (50.1) | 831 (49.5) |
Missing Data | 1 (0.49) | 2 (0.91) | ||
Histological grade | ||||
Grade 1 | 13 (6.34) | 13 (5.88) | 140 (8.3) | 145 (8.6) |
Grade 2 | 82 (40) | 92 (41.63) | 708 (42.2) | 731 (43.5) |
Grade 3 | 109 (53.17) | 114 (51.58) | 787 (46.9) | 765 (45.4) |
Grade 4 | 0 | 1 (0.45) | ||
Missing Data | 1 (0.49) | 1 (0.45) | ||
